Member Info for Morgank

So who’s selling now ?

Jupiter has gone !!
Significant Shareholders
The following shareholders amount to 3% or more of the ordinary share capital of the company.
Shares in issue: 215,405,178 £0.10 Ords
Significant Shareholders (>3%) Date Amount Holding %
Conifer Management LLC 16/06/2020 12,032,522 6.96%
Dermot Keane 16/11/2020 12,777,088 5.93%
FIL Limited 20/11/2020 tbc(*) <5%
Andrew Newland 16/11/2020 7,054,686 3.28%

I’d like to know who’s now buying all these shares ??

Great news guys, another ringing endorsement of a brilliant machine

Breast cancer is the most frequently diagnosed cancer in women with 2 million cases diagnosed globally and 240,000 cases diagnosed each year in the US. Every tumour evolves differently with time and treatment, bringing about the need for longitudinal patient monitoring. CTCs as a liquid biopsy, provides for minimally invasive, real-time monitoring of cancer patients, giving comprehensive insight into clonal evolution and the potential to provide actionable information for targeted therapy.

MD Anderson Professor and Senior Author James M. Reuben, Ph.D., M.B.A, commented:

"Here we validated the ability of the Parsortix system to isolate and harvest small numbers of cultured cells spiked into healthy donor blood in combination with downstream molecular characterisation. Harvest of captured rare cells by the Parsortix system followed by analysis using the HTG EdgeSeq assay offers the potential for multimodal characterisation of CTCs, which could be highly advantageous in clinical decision making. Furthermore, molecular characterisation of CTCs, as demonstrated in this study, has potential for the development of minimally-invasive diagnostics."

ANGLE Founder and Chief Executive, Andrew Newland, commented:

" This study demonstrates the key capabilities of the Parsortix system to isolate CTCs for multiple forms of molecular analysis and the potential for the future development of clinical diagnostics to guide individualised treatment strategies. It also further exemplifies the utility of the Parsortix system in isolating breast cancer CTCs, which is the focus for ANGLE's FDA submission made in September 2020 and currently under substantive review by the FDA. "

The research, which has been published in the peer-reviewed journal PLOS ONE, may be accessed via https://angleplc.com/library/publications/

Dr. Reuben receives research support from ANGLE, and he is compensated as a member of its Scientific Advisory Board. This financial relationship has been disclosed to MD Anderson's Conflict of Interest Committee.

For further information:


ANGLE plc +44 (0) 1483 343434
Andrew Newland, Chief Executive
Ian Griffiths, Finance Director
finnCap Ltd (NOMAD and Joint Broker)
Corporate Finance - Carl Holmes, Simon
Hicks, Teddy Whiley
ECM - Alice Lane, Sunila de Silva +44 (0)20 7220 0500
WG Partners (Joint Broker)
Nigel Barnes, Nigel Birks, Andrew Craig,
Chris Lee +44 (0) 203 705 9330
FTI Consulting
Simon Conway, Ciara Martin +44 (0) 203 727 1000
Matthew Ventimiglia (US) +1 (212) 850 5624

For Frequently Used Terms, please see the Company's website on https://angleplc.com/investor-relations/glossary/

Notes for editors

About ANGLE plc www.angleplc.com

ANGLE is a world leading liquid biopsy company with sample-to-answer solutions. ANGLE's proven patent prot

Angle PLC Parsortix can capture single cancer cell in sample

Source: RNS Non-Regulatory
TIDMAGL

Angle PLC

09 December 2020


For immediate release 9 December 2020

ANGLE plc ("the Company")

INDEPENT data PUBLISHED showing CAPABILITY of Parsortix system to capture a single cancer cell in A blood sample for analysis

Research confirms high performance of the Parsortix system to isolate CTCs for downstream analysis of over 2,500 cancer related genes

Gene transcripts detected at high levels of sensitivity

ANGLE plc (AIM:AGL OTCQX:ANPCY), a world-leading liquid biopsy company, is pleased to announce that independent data from researchers at The University of Texas MD Anderson Cancer Center, published in the peer reviewed journal PLOS ONE, demonstrates the performance of ANGLE's Parsortix(R) system in tandem with multiple downstream molecular characterisation of circulating tumour cells (CTCs).

The study used blood from healthy volunteers spiked with cancer cells from five breast cancer cell lines and one lung cancer cell line to evaluate the linearity, sensitivity, and specificity of the Parsortix system in combination with three downstream techniques for the molecular characterisation of CTCs.

The Parsortix system demonstrated strong linearity suggesting that a patient sample would reflect the frequency of CTCs in the patient's blood. Furthermore, the Parsortix system was shown to be capable of isolating a single CTC spiked into 5mL of blood. This is significant given the rarity of CTCs and the prognostic significance of even a single CTC during adjuvant treatment of breast cancer.

Using gene expression analysis methods (qRT-PCR), the authors detected gene transcripts at high sensitivity from as few as five spiked cancer cells or less. In addition, the HTG EdgeSeq nuclease protection assay, was able to profile RNA expression of over 2,500 cancer-related genes from the Parsortix system enriched cells. Such downstream analysis has the potential to provide actionable clinical insight and personalised medicine with corresponding targeted therapies as exemplified in this study by quantification of HER2 and PD-L1.

Whilst CTC enumeration is highly prognostic, molecular characterisation of CTCs has the potential to inform individualised treatment strategies and provides a repeatable minimally invasive means to monitor disease and provide targeted treatment over time. This study provides further evidence that the Parsortix system is able to capture and harvest a variety of CTCs, irrespective of their surface antigens, for downstream molecular analysis. Critically, unlike the legacy antibody-based CTC system, the Parsortix system was able to isolate and harvest mesenchymal CTCs which are known to have prognostic significance and metastatic propensity.

Breast cancer is the most frequently diagnosed cancer in women with 2 million cases diagnosed globally and 240,000 cases diagnosed each year in the US. Every tumour

418k so far, mixed buying and selling again

Sp up 1.5% @ 5.48

500k UT trade put us flat on the day

Buying again

Must be one or 2 TR1’s coming , our largest shareholder only has about 12 mil

ADVFN TOTAL VOL. 32.9 mil now

Wow 32.65. Million traded today !!

Right old buy/sell battle going on

2.037 mil traded

1.13 mil traded so far

Good early buying, hopeful of a good day and bottom in !

Vol now 3.991 mil for the day
Jupiter (Northern Trust) had below 10,770,259 @ last TR1 20 Nov ie less than 5%

3.516 mil now after late reporting

Over 3 mil and even a 1.3% sp rise, Jupiter must be near done I hope !